Phenominer Database Results (54 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 64.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days 69378 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 4.9 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69389 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 91.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69406 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 22.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69414 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 18.7 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69418 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 11.2 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69421 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 6.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69430 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 28.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69436 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 17.6 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69408 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 30.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69426 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 33.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days 69379 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 50.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69384 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 5.5 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days days 69383 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 22.6 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69396 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 15.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 31days days 69398 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 17.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69420 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 13.3 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69423 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 17 9.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69425 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 31.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69429 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 33.9 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69388 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 20.9 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days days 69393 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 18.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 31days 69395 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 11.8 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69399 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 14.1 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69410 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 11.5 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69419 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 16.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69422 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 24 33.0 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to38 days 69382 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 33.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69385 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 90.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69394 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 7.5 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69437 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 17 25.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69424 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 2.7 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69428 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 9 28.4 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69431 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 28.9 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69433 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 6 50.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69435 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 6.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69386 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 11 17.4 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 38days 69407 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 11.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69416 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 86.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69415 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 10.7 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days days 69381 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 94.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days 69390 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 26.5 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 37 days 69380 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 38.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69387 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 16.7 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 38 days 69391 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 14.3 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31 days days 69392 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69409 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 23.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69411 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 16.3 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69413 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 32.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69427 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 9 5.9 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69432 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 7.8 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69434 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 19 100.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69397 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 7 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69412 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 14 18.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69417 892